ESMO 2024 | Navigating regulatory challenges for live bacteria in cancer therapy

Jan Theys • 14 Sep 2024

ESMO 2024

General

Jan Theys, PhD, Maastricht University, Maastricht, Netherlands, discusses the unique regulatory challenges posed by using live bacteria in cancer treatment. Unlike conventional drugs, live bacteria require tailored regulatory frameworks, particularly in determining dosage and ensuring compliance with Good Manufacturing Practice (GMP) and clinical trial standards. Collaboration between researchers, medical oncologists, and regulatory bodies is essential to streamline processes, prevent contamination, and fully unlock the therapeutic potential of live bacterial treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.